Prestige Consumer Healthc... (PBH)
NYSE: PBH
· Real-Time Price · USD
83.60
0.16 (0.19%)
At close: Jun 23, 2025, 10:33 AM
Prestige Consumer Healthcare Revenue Breakdown
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | Mar 31, 2016 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analgesics Revenue | 117.7M | 117.45M | 119.26M | 119.32M | 119.14M | 114.01M | 114.18M | 119.42M | 122.17M | 119.47M | 114.55M |
| Analgesics Revenue Growth | +0.21% | -1.52% | -0.05% | +0.15% | +4.50% | -0.15% | -4.39% | -2.26% | +2.27% | +4.29% | n/a |
| Cough and Cold Revenue | 106.21M | 119.02M | 126.99M | 107.08M | 70.64M | 111.11M | 103.12M | 111.85M | 108.78M | 116.57M | 121.77M |
| Cough and Cold Revenue Growth | -10.76% | -6.27% | +18.59% | +51.58% | -36.42% | +7.74% | -7.80% | +2.81% | -6.68% | -4.27% | n/a |
| Dermatologicals Revenue | 128.95M | 129.1M | 123.74M | 120.39M | 107.08M | 103.01M | 97.97M | 96.89M | 87.35M | 85.07M | 67.09M |
| Dermatologicals Revenue Growth | -0.12% | +4.33% | +2.79% | +12.42% | +3.95% | +5.14% | +1.12% | +10.92% | +2.68% | +26.80% | n/a |
| Eye and Ear Care Revenue | 183.32M | 179.42M | 171.08M | 163.45M | 110.41M | 112.16M | 112.84M | 104.05M | 109.69M | 107.5M | 97.92M |
| Eye and Ear Care Revenue Growth | +2.17% | +4.88% | +4.67% | +48.04% | -1.56% | -0.60% | +8.44% | -5.14% | +2.04% | +9.78% | n/a |
| Gastrointestinal Revenue | 255.94M | 231.61M | 226.58M | 204.56M | 161.14M | 172.91M | 160.46M | 152.24M | 101.31M | 94.59M | 96.97M |
| Gastrointestinal Revenue Growth | +10.51% | +2.22% | +10.77% | +26.95% | -6.81% | +7.76% | +5.40% | +50.26% | +7.11% | -2.46% | n/a |
| Oral Care Revenue | 95.03M | 96.31M | 97.63M | 97.52M | 101.43M | 93.2M | 103.43M | 111M | 108.1M | 51.13M | 46.4M |
| Oral Care Revenue Growth | -1.32% | -1.35% | +0.11% | -3.85% | +8.83% | -9.89% | -6.82% | +2.69% | +111.44% | +10.19% | n/a |
| Other OTC Revenue | 13.78M | 12.03M | 11.1M | 9.98M | 5.43M | 5.07M | 5.48M | 5.71M | 5.83M | 6.1M | 6.21M |
| Other OTC Revenue Growth | +14.58% | +8.36% | +11.14% | +84.02% | +7.13% | -7.62% | -3.91% | -2.11% | -4.43% | -1.87% | n/a |
| Women's Health Revenue | 236.83M | 240.42M | 251.35M | 264.51M | 268.1M | 251.55M | 258.48M | 259.38M | 150.88M | 135.17M | 73.77M |
| Women's Health Revenue Growth | -1.49% | -4.35% | -4.97% | -1.34% | +6.58% | -2.68% | -0.35% | +71.91% | +11.63% | +83.23% | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2018 | Mar 31, 2017 | Mar 31, 2016 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|
| North American Otc Healthcare Revenue | 960.01M | 958.26M | 973.77M | 868.87M | 720.82M | 657.87M | 566.26M |
| North American Otc Healthcare Revenue Growth | +0.18% | -1.59% | +12.07% | +20.54% | +9.57% | +16.18% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 64.05M | 64.13M | 67.48M | 68.28M | 63.98M | 65.47M | 66.1M | 63.92M | 58.53M | 56.96M | 70.26M | 66.67M | 64.75M | 66.22M | 72.98M | 61.91M | 60.24M | 59.48M | 58.73M | 47.68M | 63.75M | 54.87M | 61.18M | 56.51M | 55.73M | 54.99M | 61.08M | 61.05M | 157.13M | 57.04M | 60.76M | 57.28M | 70.21M | 52.81M | 47.39M | 47.09M | 46.78M | 48.07M | 44.35M | 44.01M | 43.05M |
| Selling, General, and Administrative Revenue Growth | -0.11% | -4.96% | -1.17% | +6.71% | -2.27% | -0.95% | +3.41% | +9.20% | +2.77% | -18.93% | +5.39% | +2.97% | -2.23% | -9.26% | +17.88% | +2.77% | +1.28% | +1.27% | +23.16% | -25.20% | +16.19% | -10.32% | +8.27% | +1.39% | +1.35% | -9.97% | +0.04% | -61.15% | +175.47% | -6.11% | +6.07% | -18.42% | +32.94% | +11.45% | +0.63% | +0.66% | -2.68% | +8.38% | +0.78% | +2.23% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue | 37M | 37.95M | 41.41M | 39.37M | 37.52M | 39.47M | 40.1M | 36.23M | 30.87M | 30.42M | 43.82M | 39.95M | 36.94M | 40.24M | 40.73M | 39.44M | 36.42M | 38.08M | 38.34M | 27.75M | 40.17M | 33.56M | 38.67M | 34.8M | 34.43M | 34.5M | 37.04M | 37.11M | 35.32M | 35.84M | 39.19M | 36.94M | 41.45M | 30.68M | 28.59M | 27.64M | 26.55M | 29.93M | 27.89M | 26.42M | 25.37M |
| Sales and Marketing Revenue Growth | -2.48% | -8.37% | +5.19% | +4.93% | -4.94% | -1.59% | +10.68% | +17.37% | +1.46% | -30.57% | +9.68% | +8.17% | -8.21% | -1.21% | +3.27% | +8.30% | -4.37% | -0.68% | +38.17% | -30.91% | +19.69% | -13.21% | +11.11% | +1.07% | -0.21% | -6.85% | -0.19% | +5.07% | -1.44% | -8.56% | +6.07% | -10.87% | +35.10% | +7.31% | +3.46% | +4.08% | -11.30% | +7.32% | +5.57% | +4.16% | n/a |